Standard BioTools (NASDAQ:LAB) Director Purchases $540,000.00 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock in a transaction dated Thursday, November 13th. The stock was acquired at an average cost of $1.20 per share, with a total value of $540,000.00. Following the completion of the acquisition, the director directly owned 62,500,000 shares in the company, valued at approximately $75,000,000. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.22 per share, for a total transaction of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.24 per share, for a total transaction of $310,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.17 per share, for a total transaction of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L acquired 100,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.29 per share, with a total value of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.27 per share, for a total transaction of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L purchased 200,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.24 per share, with a total value of $248,000.00.

Standard BioTools Trading Down 2.4%

Standard BioTools stock traded down $0.03 during mid-day trading on Monday, reaching $1.21. The company’s stock had a trading volume of 1,308,580 shares, compared to its average volume of 1,658,374. The firm has a market cap of $465.32 million, a price-to-earnings ratio of -3.78 and a beta of 1.25. Standard BioTools Inc. has a twelve month low of $0.92 and a twelve month high of $2.25. The business has a 50 day moving average price of $1.29 and a 200-day moving average price of $1.23.

Institutional Trading of Standard BioTools

Large investors have recently made changes to their positions in the business. Jump Financial LLC acquired a new position in Standard BioTools in the first quarter valued at approximately $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after buying an additional 14,541 shares in the last quarter. CWM LLC boosted its stake in Standard BioTools by 101.8% in the 1st quarter. CWM LLC now owns 29,705 shares of the company’s stock worth $32,000 after purchasing an additional 14,984 shares during the period. Russell Investments Group Ltd. raised its position in Standard BioTools by 2,989.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Standard BioTools in the first quarter valued at approximately $35,000. Institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

LAB has been the topic of several recent analyst reports. Cowen cut Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. TD Cowen reduced their target price on Standard BioTools from $1.55 to $1.35 and set a “hold” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.